3/25
05:04 pm
tsvt
2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
Low
Report
2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
3/25
04:05 pm
tsvt
2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results
Low
Report
2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results
3/24
02:03 am
tsvt
2seventy bio, Inc. (NASDAQ: TSVT) had its "sell (e+)" rating re-affirmed by analysts at Weiss Ratings.
Low
Report
2seventy bio, Inc. (NASDAQ: TSVT) had its "sell (e+)" rating re-affirmed by analysts at Weiss Ratings.
3/14
11:24 am
tsvt
2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT
Low
Report
2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT
3/14
08:36 am
tsvt
2seventy bio, Inc. (NASDAQ: TSVT) had its price target lowered by analysts at Morgan Stanley from $6.00 to $5.00. They now have an "equal weight" rating on the stock.
Neutral
Report
2seventy bio, Inc. (NASDAQ: TSVT) had its price target lowered by analysts at Morgan Stanley from $6.00 to $5.00. They now have an "equal weight" rating on the stock.
3/13
06:28 am
tsvt
2seventy bio, Inc. (NASDAQ: TSVT) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Neutral
Report
2seventy bio, Inc. (NASDAQ: TSVT) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
3/12
07:13 pm
tsvt
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TSVT, BRDG, GB on Behalf of Shareholders
Low
Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TSVT, BRDG, GB on Behalf of Shareholders
3/12
01:47 pm
tsvt
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of 2seventy bio, Inc. - TSVT
Neutral
Report
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of 2seventy bio, Inc. - TSVT
3/12
12:46 pm
tsvt
Bristol-Myers Squibb To Acquire 2seventy bio - A Sad But Inevitable End To A Cell Therapy Pioneer [Seeking Alpha]
Low
Report
Bristol-Myers Squibb To Acquire 2seventy bio - A Sad But Inevitable End To A Cell Therapy Pioneer [Seeking Alpha]
3/11
08:18 pm
tsvt
Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders
Low
Report
Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders
3/11
03:35 pm
tsvt
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)
Neutral
Report
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)
3/11
03:31 pm
tsvt
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.
Neutral
Report
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.
3/11
08:44 am
tsvt
TSVT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 2seventy bio, Inc. Is Fair to Shareholders
Low
Report
TSVT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 2seventy bio, Inc. Is Fair to Shareholders
3/11
08:35 am
tsvt
2seventy bio, Inc. (NASDAQ: TSVT) had its "market perform" rating re-affirmed by analysts at Leerink Partners. They now have a $5.00 price target on the stock, down previously from $9.00.
Low
Report
2seventy bio, Inc. (NASDAQ: TSVT) had its "market perform" rating re-affirmed by analysts at Leerink Partners. They now have a $5.00 price target on the stock, down previously from $9.00.
3/10
10:17 pm
tsvt
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
High
Report
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
3/8
01:33 am
tsvt
2seventy bio, Inc. (NASDAQ: TSVT) had its "sell (d-)" rating re-affirmed by analysts at Weiss Ratings.
Medium
Report
2seventy bio, Inc. (NASDAQ: TSVT) had its "sell (d-)" rating re-affirmed by analysts at Weiss Ratings.
2/25
07:00 am
tsvt
2seventy bio to Participate in the 2025 TD Cowen Healthcare Conference
High
Report
2seventy bio to Participate in the 2025 TD Cowen Healthcare Conference
2/20
02:31 am
tsvt
2seventy bio, Inc. (NASDAQ: TSVT) had its "sell (d-)" rating re-affirmed by analysts at Weiss Ratings.
Neutral
Report
2seventy bio, Inc. (NASDAQ: TSVT) had its "sell (d-)" rating re-affirmed by analysts at Weiss Ratings.
2/6
07:21 am
tsvt
2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results [Yahoo! Finance]
Medium
Report
2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results [Yahoo! Finance]
2/6
07:03 am
tsvt
2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results
Medium
Report
2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results
2/4
02:07 am
tsvt
2seventy bio, Inc. (NASDAQ: TSVT) had its "sell (e+)" rating re-affirmed by analysts at Weiss Ratings.
Medium
Report
2seventy bio, Inc. (NASDAQ: TSVT) had its "sell (e+)" rating re-affirmed by analysts at Weiss Ratings.
1/19
06:36 pm
tsvt
2seventy bio, Inc. (NASDAQ: TSVT) had its "sell (e+)" rating re-affirmed by analysts at Weiss Ratings.
Low
Report
2seventy bio, Inc. (NASDAQ: TSVT) had its "sell (e+)" rating re-affirmed by analysts at Weiss Ratings.
1/19
06:34 pm
tsvt
2seventy bio, Inc. (NASDAQ: TSVT) had its "sell (e+)" rating re-affirmed by analysts at Weiss Ratings.
Low
Report
2seventy bio, Inc. (NASDAQ: TSVT) had its "sell (e+)" rating re-affirmed by analysts at Weiss Ratings.